Search results
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi...
Benzinga via Yahoo Finance· 9 hours agoThe terms of the agreement include: A co-exclusive license to co-commercialize Novavax’s current...
Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop...
CNBC· 17 hours agoNovavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to...
Novavax stock doubles after Sanofi deal marks 'new chapter' for company
Yahoo Finance via AOL· 3 hours agoNovavax stock (NVAX) skyrocketed on Friday, nearly doubling on the news French drug and vaccine...
Novavax gets a lifeline with Sanofi vaccine pact
BioPharma Dive via Yahoo Finance· 14 hours agoSanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination...
Novavax Shares Surge Over 130% After $1.4 Billion Covid Shot Deal With Sanofi
Forbes· 18 hours agoNovavax shares surged 132% to $10.41 as of 10:00 a.m. Friday morning, following an earlier surge in...
Maryland-based Novavax soars on big vaccine deal - WTOP News
WTOP Washington· 10 hours agoGaithersburg, Maryland-based Novavax has signed a $1.2 billion licensing agreement with French...
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with Strategic Partnerships and Cost ...
GuruFocus.com via Yahoo Finance· 5 hours agoFurthermore, the company is preparing for the upcoming vaccination seasons by advancing its COVID-19 vaccine and initiating Phase 3 trials for its
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine...
WJTV Jackson· 17 hours ago...worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan and South Korea where Novavax has existing partnership agreements); a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines while Novavax retains the...
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
WKBN 27 Youngstown· 17 hours ago...combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to Phase 3 COVID-19-Influenza...
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with
Guru Focus· 6 hours agoThe company, a prominent player in the biotechnology sector focusing on the development of vaccines, reported a net loss of $147.55 million with a loss per share of $1.05.